3(R,S,)-Amino-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one | 146373-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3(R,S,)-Amino-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
• 英文别名: 3-amino-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one；3-amino-5-cyclohexyl-2,3-dihydro-1-methyl-1H-1,4-benzodiazepin-2-one；3(R,S)-amino-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one；3-amino-5-cyclohexyl-1-methyl-3H-1,4-benzodiazepin-2-one
• CAS: 146373-98-0
• 化学式: C₁₆H₂₁N₃O
• 分子量: 271.362
• InChiKey: WPUGPPDGRWVNOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  异氰酸间甲苯酯 、 3(R,S,)-Amino-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one 以 四氢呋喃 为溶剂， 生成 1-(5-Cyclohexyl-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea
  参考文献：
  名称：

  Carbamate Oxime Reduction: A New Route to C3-Amino-1,4-benzodiazepines

  摘要：

  描述了一种温和的还原方法，将C3-氧肟基-1,4-苯二氮杂平还原为C3-氨基衍生物。关键步骤涉及形成一个碳酸酯氧肟中间体。与母体C3-氧肟相比，C3-(乙氨基羰基)氧肟基-1,4-苯二氮杂平对氢化具有更高的反应性，使得在常温下使用碳载钯进行还原成为可能。这种温和的条件更适合于像3,5-二氨基-1,4-苯二氮杂平这样的敏感胺。

  DOI：

  10.1055/s-1994-25513
• 作为产物：
  描述：

  氨甲酸,(5-环己基-2,3-二氢-1-甲基-2-羰基-1H-1,4-苯并二氮卓-3-基)-,苯基甲基酯 在 氮气 、 乙醚 、 水 、 sodium hydroxide 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 silica gel 、 二氯甲烷 、 甲醇 作用下， 以 溶剂黄146 、 乙醚 为溶剂， 反应 1.75h， 以methanol as the eluant, to afford the title compound (1.6 g)的产率得到3(R,S,)-Amino-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
  参考文献：
  名称：

  Benzodiazepine derivatives

  摘要：

  公式（I）的化合物：##STR1##其中R.sub.1是氢或指定的可选取代烷基，R.sup.2是指定的可选取代苯基或吡啶基，x为0、1、2或3，R.sup.3是指定的烷基、卤素或氨基，R.sup.4是指定的环烷基或双环烷基；以及它们的盐和前药，可用作胆囊收缩素和胃泌素受体的拮抗剂。

  公开号：

  US05556969A1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Benzodiazepine derivatives, compositions containing them and their use in therapy
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0514133A1

  公开（公告）日：1992-11-19

  Compounds of formula (I), and salts and prodrugs thereof wherein:    R¹ represents optionally substituted C₁₋₆alkyl or C₃₋₇cycloalkyl;    R² represents an optionally substituted phenyl or pyridyl group;    R³ represents C₁₋₆ alkyl or halo;    R⁴ represents C₃₋₇ cycloalkyl;    X is 0, 1, 2 or 3; are CCK and/or gastrin antagonists. They and compositions thereof are therefore useful in therapy.

  公式(I)的化合物，以及其盐和前药，其中：R¹代表可选地取代的C₁₋₆烷基或C₃₋₇环烷基；R²代表可选地取代的苯基或吡啶基团；R³代表C₁₋₆烷基或卤素；R⁴代表C₃₇环烷基；X是0、1、2或3；是CCK和/或胃泌素拮抗剂。它们及其组合物因此在治疗中是有用的。
• Benzodiazepine derivatives
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05556969A1

  公开（公告）日：1996-09-17

  Compounds of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or specified optionally substituted alkyl, R.sup.2 is specified optionally substituted phenyl or pyridyl, x is 0, 1, 2 or 3, R.sup.3 is a specified alkyl, halo or amino and R.sup.4 is specified cycoalkyl or bicycloalkyl; and salts and prodrugs thereof, are useful as antagonists of cholecystokin and gastrin receptors.

  公式(I)的化合物：##STR1## 其中R1是氢或指定的可选取代烷基，R2是指定的可选取代苯基或吡啶基，x是0、1、2或3，R3是指定的烷基、卤素或氨基，R4是指定的环烷基或双环烷基；以及它们的盐和前药，可用作胆囊激肽和胃泌素受体的拮抗剂。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20040106598A1

  公开（公告）日：2004-06-03

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制β-淀粉样肽释放和/或合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还公开了包括抑制β-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。